Pulsenmore Ltd (PLSM) News & EventsPLSMNews & EventsPulsenmore Ltd

Pulsenmore Selected for Israel's Healthcare AI Regulatory Sandbox Program

Pulsenmore announced that it has been selected to participate in Israel's Healthcare AI Regulatory Sandbox Program, established by the Israel Innovation Authority and the Ministry of Health. Pulsenmore will receive funding from the IIA as part of a project. The program is designed to accelerate the adoption of breakthrough healthcare AI technologies through a unique regulatory framework that enables companies to develop, evaluate and clinically validate innovative solutions in close collaboration with regulators and the healthcare system. Its objective is to establish a clear and efficient pathway for the integration of these technologies into healthcare systems in Israel and worldwide.

Company Not Selling Shares, Stockholders Offering 3.125M Shares

This filing relates to the offer and sale from time to time by the selling stockholders of up to 3.125M ordinary shares. The company is not selling any shares under this prospectus and will not receive any of the proceeds from the sale of shares by the selling stockholders.

Pulsenmore Enters Agreement to Issue 1,562,500 Shares with Institutional Investor

Pulsenmore announced that it has entered into a securities purchase agreement with a healthcare-focused institutional investor, for the purchase and sale of 1,562,500 ordinary shares and ordinary warrants to purchase up to 1,562,500 ordinary shares in a private placement at a combined purchase price of $4.80 per ordinary share and accompanying warrant, representing a premium to the Nasdaq Minimum Price under Nasdaq rules. The gross proceeds from the offering are expected to be approximately $7.5M, before deducting placement agent commissions and other estimated offering expenses. The ordinary warrants will have an exercise price of $4.80 per share, will be exercisable immediately upon issuance, and will expire five years following the date of issuance. The pre-funded warrants will have at an exercise price of $0.0001 per share and will be exercisable immediately until exercised in full. The closing of the Offering is expected to occur on or about June 26. A.G.P./Alliance Global Partners is acting as the sole placement agent for the Offering.